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for mortality with respect to either culprit vessel (log-rank-p-val-
ue¼0.54) or proximal vs. mid/distal location of the culprit lesion
within the vessel (log-rank-p-value¼0.45). This was also true after
multivariable adjustment, independent predictors of outcome were
serum lactate, success of revascularization, age, serum creatinine,
prior stroke, known peripheral artery disease and left bundle branch
block in admission electrocardiogram.
CONCLUSIONS For patients with CS complicating myocardial infarction,
the culprit lesion localization seems to be unrelated with mortality.
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BACKGROUND The Glucagon Like Peptide 1 receptor agonist exena-
tide is an incretin based compound used for glycemic control in pa-
tients with type 2 diabetes mellitus (DM) and has previously been
demonstrated to have cardioprotective properties. This double blin-
ded, randomized clinical trial studies the effect of exenatide treat-
ment on myocardial salvage in ST Elevated Myocardial Infarction
(STEMI) patients who successfully underwent primary Percutaneous
Coronary Intervention (PCI).
METHODS STEMI patients were randomly assigned to either intrave-
nous exenatide or placebo. Study medication was started prior to PCI
using 10 mg/h for 30minutes followed by 0.84 mg/h for 72h. Patientswith
a previous STEMI, Thrombolysis In Myocardial Infarction ﬂow 2 of 3,
multi vessel disease, or DM were excluded. Magnetic resonance imag-
ing was performed within 2-7 days after PCI, to determine left ventric-
ular (LV) volumes and ejection fraction (EF), infarct size and area at risk
(using T2-weighted hyperintensity (T2W) and late enhancement
endocardial surface area (ESA)). The primary endpoint of myocardial
salvage index (MSI) was deﬁned as the difference between the area at
risk and total infarct size, as ratio of the area at risk. Secondary end-
points were major cardiovascular events ((MACE) deﬁned as cardiac
death, repeat STEMI, coronary artery bypass grafting or repeat PCI), LV
end systolic volume (ESV), LV EF and infarct size.
RESULTS In total 91 patients (age 57.4  10.1 years, 76% male)
completed the study. There were no baseline differences between
both groups. Symptom to balloon time was 18185 vs. 20195 min
(p¼0.24) for exenatide (n¼42) and placebo (n¼49) respectively. Pa-
tients receiving exenatide had signiﬁcantly more episodes of nausea
early after study drug initiation (16 vs 4 patients, p<0.001), but this
did not lead to study discontinuation and was treated successfully
with metoclopramide in all cases. The MSI was not signiﬁcantly
different between both groups (with ESA 0.30  0.26 vs 0.26  0.22,
p¼0.43 and with T2W 0.35  0.25 vs 0.33  0.22, p¼0.65 for exenatide
vs placebo respectively). There were also no differences in LV ESV
(61.3  26.0 vs 54.9  25.9 ml/m2, p¼0.259), LV EF (52.6  7.7 vs. 52.4
 6.9%, p¼0.53) and infarct size (18.8  13.2 vs. 18.8  11.3% of LV
mass, p¼0.965). No MACE occurred during the in-hospital phase.
CONCLUSIONS Our exenatide treatment protocol does not improve
myocardial salvage in STEMI patients successfully treated with pri-
mary PCI. This is incongruent with previous clinical trail results.
Differences in the exenatide treatment protocols are the most obvious
reason for the ambiguous trial results. Further studies are needed to
establish the exact role and the optimal treatment protocol of exe-
natide in this group of patients.
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BACKGROUND Limited information is available about the efﬁcacy
and outcomes after primary percutaneous coronary intervention (P-
PCI) in very elderly patients (pts) with ST Elevation Myocardial
Infarction (STEMI).
METHODS 23 nonagenarian pts were treated (1% of the total STEMI
population underwent P-PCI). We evaluated in-hospital, 6-months
and 1 year-mortality in a retrospective analysis of nonagenarian pts
admitted at our Department with STEMI and treated with P-PCI from
November 2004 and December 2013. A bivariate analysis was carried
on with exact Fisher’s test, identifying those variables associated with
mortality. Odds ratios (ORs) from univariate logistic regression ana-
lyses were performed.
RESULTS All pts received aspirin and 300 mg clopidogrel loading
dose. Mean age: 91.2 yrs (range 90-96). 65% was women. Mean left
ventricular ejection fraction (LVEF) at the admission: 38.9% (23% of
pts with LVEF<35%). Advanced Killip class (3-4) at presentation: 10
pts (43%). Baseline characteristic: 13% of pts with prior revasculari-
zation, 17.3% prior stroke, 21.7% diabetes, 43% hypertension, 8.6%
atrial ﬁbrillation. No dementia (good mental status). Mean renal
function evaluated by creatinine clearance measured by the Cock-
croft–Gault equation: 38.7 mL/min (range 16.8 – 72.9). Mean hemo-
globin value: 13.7 gr/dL. Mean number of vessels treated per pts: 1.04,
showing a strategy of treating the culprit vessel only. 3 left main (LM),
8 left anterior descending coronary artery (LAD), 4 circumﬂex coro-
nary artery, 8 right coronary artery (RCA). The radial approach was
performed in 65% (100% of cases from 2012). The proportion of radial
to femoral shift was 6%. An average of 1.26 stents per pt were
implanted (100% were bare metal stent). In 4 pts we performed P-PCI
without stent. No Glycoprotein IIb/IIIa were used. Intra-aortic balloon
pump was implanted in 1 pt. The TIMI ﬂow 2-3 post P-PCI was ach-
ieved in 78.2% of pts (angiographic success was achieved in 20/23 pts).
In 1 pt occurred acute renal failure post P-PCI and in 1 pt occurred
major bleeding; no stroke. The overall in-hospital mortality rate was
34.7% (one pt died during the procedure). Cumulative mortality after
discharge at 6 months was 14% and at 1 year was 28%. LVEF<30
showed a higher risk of in-hospital mortality and cumulative mortality
at 6 months. Killip3 showed a higher risk of in-hospital mortality. LM
and LAD showed a higher risk of in-hospital mortality, cumulative
mortality at 6 months and at 1 year.
CONCLUSIONS Our data suggest that primary P-PCI in nonagenarian
pts can be performed with an acceptable bleeding risk. The in-hospital
mortality is signiﬁcant but the cumulative mortality at 6 months and 1
year is low, showed a good success rate of the P-PCI strategy. The
radial approach is feasible and safe. The invasive strategy in selected
very elderly population should be offered. Further studies are needed
to evaluate the beneﬁt of P-PCI versus non P-PCI strategy in the very
elderly population.
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BACKGROUND The left ventricular global function index (LVGFI) is a
novel indicator of left ventricular performance. Its prognostic value in
patients after ST-segment elevation myocardial infarction (STEMI) is
unknown. We sought to evaluate the prognostic value of LVGFI
measured by cardiovascular magnetic resonance (CMR) imaging after
STEMI.
METHODS Two hundred eligible STEMI patients (5611 years, 16 %
female) revascularized by primary percutaneous coronary interven-
tion (PCI) were followed-up for 3.1 [2-4.1] years for major adverse
cardiac events (MACE). MACE was deﬁned as a composite of death,
nonfatal myocardial re-infarction and new congestive heart failure.
All patients underwent CMR imaging within 2 [2-4] days after STEMI.
Late enhancement and cine images were acquired to assess myocar-
dial injury as well as myocardial function, including LVGFI.
RESULTS Patients suffering a MACE event (n ¼ 20, 10%) had a
signiﬁcantly lower LVGFI (p ¼ 0.001). In Kaplan-Meier analysis, a
